This article is more than 5 years old. Information may no longer be current.
Diabetic retinopathy drug in trials
THOROFARE, N.J. — An oral drug to treat diabetic retinopathy appears to be safe in two clinical trials to date.
The systemic drug, currently dubbed Ly333531, is in phase 2 and phase 3 trials to evaluate its safety and efficacy in the treatment of diabetic retinopathy and diabetic macular edema.
Lloyd P. Aiello, MD, PhD, of Harvard University, lead investigator of the studies, told Ocular Surgery News that studies of the drug are still masked and undergoing evaluation. He presented an update on Ly333531 at a meeting in New Orleans sponsored by Eli Lilly and Co., the drug's developers.
In the trials, patients receive either a placebo or one of several doses of the compound. Results of the study should be available by late 2002, Dr. Aiello said.
More on the study is published in the Jan. 1 edition of Ocular Surgery News.